{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:21:19Z","timestamp":1785450079969,"version":"3.56.0"},"reference-count":24,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2015]]},"DOI":"10.1536\/ihj.14-335","type":"journal-article","created":{"date-parts":[[2015,4,26]],"date-time":"2015-04-26T18:05:23Z","timestamp":1430071523000},"page":"309-313","source":"Crossref","is-referenced-by-count":13,"title":["Clinical Significance of High-Sensitivity Cardiac Troponin T in Patients With Dilated Cardiomyopathy"],"prefix":"10.1536","volume":"56","author":[{"given":"Yuichi","family":"Baba","sequence":"first","affiliation":[{"name":"Department of Cardiology, Neurology and Aging Science, Kochi Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Neurology and Aging Science, Kochi Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kochi Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Hirota","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Neurology and Aging Science, Kochi Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Tanioka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Neurology and Aging Science, Kochi Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Neurology and Aging Science, Kochi Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kochi Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Neurology and Aging Science, Kochi Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429-35.","DOI":"10.1056\/NEJM198706043162301"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302.","DOI":"10.1056\/NEJM199108013250501"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Granger CB, McMurray JJ, Yusuf S, <i>et al<\/i>. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6.","DOI":"10.1016\/S0140-6736(03)14284-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Packer M, Bristow MR, Cohn JN, <i>et al<\/i>. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.","DOI":"10.1056\/NEJM199605233342101"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mori Y, Nishikawa Y, Kobayashi, Hiramatsu K. Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol. Int Heart J 2013; 54: 15-22.","DOI":"10.1536\/ihj.54.15"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cleland JG, Daubert JC, Erdmann E, <i>et al<\/i>. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49.","DOI":"10.1056\/NEJMoa050496"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331: 1564-75. (Review)","DOI":"10.1056\/NEJM199412083312307"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Anand IS, Fisher LD, Chiang YT, <i>et al<\/i>. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-83.","DOI":"10.1161\/01.CIR.0000054164.99881.00"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Velagaleti RS, Gona P, Larson MG, <i>et al<\/i>. Multimarker approach for the prediction of heart failure incidence in the community. Circulation 2010; 122: 1700-6.","DOI":"10.1161\/CIRCULATIONAHA.109.929661"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Takeishi Y. Biomarkers in heart failure. Int Heart J 2014; 55: 474-81. (Review)","DOI":"10.1536\/ihj.14-267"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sato Y, Yamada T, Taniguchi R, <i>et al<\/i>. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103: 369-74.","DOI":"10.1161\/01.CIR.103.3.369"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108: 833-8.","DOI":"10.1161\/01.CIR.0000084543.79097.34"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kawahara C, Tsutamoto T, Nishiyama K, <i>et al<\/i>. Prognostic role of high-sensitivity cardiac troponin T in patients with nonischemic dilated cardiomyopathy. Circ J 2011; 75: 656-61.","DOI":"10.1253\/circj.CJ-10-0837"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Okamoto R, Hirashiki A, Cheng XW, <i>et al<\/i>. Usefulness of serum cardiac troponins T and I to predict cardiac molecular changes and cardiac damage in patients with hypertrophic cardiomyopathy. Int Heart J 2013; 54: 202-6.","DOI":"10.1536\/ihj.54.202"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999; 100: 999-1008. (Review)","DOI":"10.1161\/01.CIR.100.9.999"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Packer M. Pathophysiology of chronic heart failure. Lancet 1992; 340: 88-92. (Review)","DOI":"10.1016\/0140-6736(92)90405-R"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Packer M. Treatment of chronic heart failure. Lancet 1992; 340: 92-5. (Review)","DOI":"10.1016\/0140-6736(92)90406-S"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Baig MK, Mahon N, McKenna WJ, <i>et al<\/i>. The pathophysiology of advanced heart failure. Am Heart J 1998; 135: S216-30. (Review)","DOI":"10.1016\/S0002-8703(98)70252-2"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet 1998; 352: SI8-14. (Review)","DOI":"10.1016\/S0140-6736(98)90311-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Givertz MM, Colucci WS. New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet 1998; 352: SI34-8. (Review)","DOI":"10.1016\/S0140-6736(98)90017-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Reichlin T, Hochholzer W, Bassetti S, <i>et al<\/i>. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361: 858-67.","DOI":"10.1056\/NEJMoa0900428"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Latini R, Masson S, Anand IS, <i>et al<\/i>. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007; 116: 1242-9.","DOI":"10.1161\/CIRCULATIONAHA.106.655076"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:07:40Z","timestamp":1566605260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/56\/3\/56_14-335\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.14-335","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}